Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Galapagos NV

< Previous 1 2 Next >
Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
From Galapagos NV
Via GlobeNewswire
Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024
From Galapagos NV
Via GlobeNewswire
Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update
From Galapagos NV
Via GlobeNewswire
Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth
From Galapagos NV
Via GlobeNewswire
Galapagos receives transparency notification from EcoR1 Capital
From Galapagos NV
Via GlobeNewswire
Galapagos receives transparency notification from EcoR1 Capital
From Galapagos NV
Via GlobeNewswire
Galapagos receives transparency notification from FMR LLC
From Galapagos NV
Via GlobeNewswire
Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma
From Galapagos NV
Via GlobeNewswire
Galapagos receives transparency notification from FMR LLC
From Galapagos NV
Via GlobeNewswire
Galapagos reports half-year 2024 financial results and provides second quarter business update
From Galapagos NV
Via GlobeNewswire
Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024
From Galapagos NV
Via GlobeNewswire
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications
From Galapagos NV
Via GlobeNewswire
Galapagos creates new subscription right plans
From Galapagos NV
Via GlobeNewswire
Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ decentralized CAR-T manufacturing network in the U.S.
From Galapagos NV
Via GlobeNewswire
Galapagos reports first quarter 2024 financial results
From Galapagos NV
Via GlobeNewswire
Galapagos’ shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024
From Galapagos NV
Via GlobeNewswire
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
From Galapagos NV
Via GlobeNewswire
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
From Galapagos NV
Via GlobeNewswire
Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board
From Galapagos NV
Via GlobeNewswire
Galapagos announces full year 2023 results and outlook for 2024
From Galapagos NV
Via GlobeNewswire
Galapagos presents at EBMT-EHA annual meeting 2024
From Galapagos NV
Via GlobeNewswire
Galapagos completes transaction to transfer Jyseleca® business to Alfasigma
From Galapagos NV
Via GlobeNewswire
Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further expand its decentralized CAR-T manufacturing network in the U.S.
From Galapagos NV
Via GlobeNewswire
Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology
From Galapagos NV
Via GlobeNewswire
Galapagos signs agreement to transfer Jyseleca® business to Alfasigma
From Galapagos NV
Via GlobeNewswire
Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301
From Galapagos NV
Via GlobeNewswire
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101
From Galapagos NV
Via GlobeNewswire
Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at ASH 2023
From Galapagos NV
Via GlobeNewswire
Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023
From Galapagos NV
Via GlobeNewswire
Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma
From Galapagos NV
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.